Biofrontera is a biopharmaceutical company that develops and distributes dermatological drugs, with Ameluz® its lead prescription drug for photodynamic therapy.
Which risks could break the thesis, and what would warn of them?
Biofrontera's revenue is concentrated in Germany, where the main growth driver lifted revenue 54.4% to EUR 6.8 million, and part of that sales growth reflected temporary wholesaler stocking. Management expects that stocking effect to unwind in the coming months once inventory levels normalize.
Based on current corporate planning, the Group expects to hold sufficient liquidity to meet all obligations for at least the next twelve months. Approval of further indications depends on clinical trials being conducted first.
2Product Overview
What does the product do for its buyer, and how is it delivered?
Ameluz is Biofrontera's lead topical prescription photodynamic therapy drug for certain superficial skin cancers and their precursors, delivered as a medication that modified cells absorb and convert into a substance that can be activated by light.
Ameluz has been marketed across the EU since 2012. Biofrontera seeks US approval for Ameluz to treat superficial basal cell carcinoma, acne, and additional actinic keratosis indications on areas beyond the face and scalp.